This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy).
Patient Stories
February 22, 2024
In the fall of 2021, Katie had just begun a new position as a Clinical Social Worker in Tufts Medical Center’s Emergency Department. Less than two months later, Katie’s father Jim drove himself to his local emergency room and was diagnosed with myocarditis, an infection of the heart. While some patients with myocarditis fight off the infection, Jim took a turn for the worse and was transported by ambulance to Tufts MC.